IGM is the latest biotech to focus on the potential for T cell engagers to treat inflammatory conditions. Elsewhere, Metsera signed a manufacturing deal and UCB started a first-of-its-kind trial.

Moderna doses the first participant in a phase III study evaluating its mRNA norovirus vaccine candidate, mRNA-1403, in the ...

A judge has rejected a request to throw out the conviction of a movie armorer in the fatal shooting of a cinematographer by ...

"Saturday Night Live" kicked off its 50th season ready to take on the 2024 presidential campaign, and it finally revealed who was tapped to play key figures, including Minnesota Gov.

CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / (NASDAQ:MRNA) today announced that the first participant in the U.S. has ...

Moderna also anticipates reporting interim Phase III CMVictory data on its mRNA-1647 candidate within the year and is preparing to commence a Phase III trial for its norovirus vaccine mRNA-1403.